Tech Company Financing Transactions
Incysus Therapeutics Funding Round
Bios Partners and private investors invested in a $10 million Series A venture round for Incysus Therapeutics. The funding round closed on 1/4/2019.
Transaction Overview
Company Name
Announced On
1/4/2019
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series A
Investors
Bios Partners (Lead Investor) (Travis Whitfill)
Proceeds Purpose
The new funding validates our business plan and approach. It will enable us to continue to build the team, while expanding the capabilities and opportunities of this cutting-edge scientific platform as we initiate clinical trials for blood and solid tumor cancers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
79 Madison Ave.
New York, NY 10016
USA
New York, NY 10016
USA
Phone
Website
Email Address
Overview
Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta T cells, the Company's technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Ho
Chief Medical Officer
Lou Vaickus
Chief Scientific Officer
Lawrence Lamb
VP - Operations
Melissa Beelen
VP - Regulatory Affairs
Rozanna Yaing
Browse more venture capital transactions:
Prev: 1/4/2019: FreightPOP venture capital transaction
Next: 1/7/2019: Banyan Biomarkers venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs